Back
Results - Announcements
Corona Remedies Ltd consolidated sales up 19.64% on year in Q2FY2026, net profit jumped 32.61%
31-Jul-2026, 08:32
Corona Remedies Ltd share price softened by 0.77% to Rs 2089.65. The Company's net profit soared by 32.61% to Rs 60.11 crore, while revenue from operations gained 19.64% to Rs 422.43 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 23.86 lakh crore, easing 6%. It has inched up 2.79% over last one week and surged by 15.59% in last one month while the market capitalization of Corona Remedies Ltd has slipped by 0.78% and 21.60% in the same period respectively. Profit before tax (PBT) of Corona Remedies Ltd stood at Rs 80.36 crore in Q2 FY26, surging by 32.41% year-on-year, and rallying 46.80% quarter-on-quarter. EBITDA came in at Rs 90 crore, expanding by 32.79% YoY and jumping 55.38% sequentially. Total expenses increased by 13.66% to Rs 342.54 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 32.65 crore, advancing by 17.74% YoY, while employee benefits expense was at Rs 122.09 crore, witnessing a strong rise of 14.50% YoY. For the TTM ended FY26, revenue from operations grew 17.28% to Rs 1403.18 crore, while net profit saw a strong growth of 23.88% to Rs 185.12 crore, compared to previous TTM. EBITDA surged by 23376% to Rs 282.79 crore, and PBT surged 21.10% to Rs 240.42 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 229.48 crore in FY26, as against Rs 190.5 crore in FY25. Corona Remedies Ltd rallied 45.40% in last one year, significantly outperforming the benchmark BSE Sensex which has slipped by 4.36% during the same period.
Corona Remedies Ltd share price softened by 0.77% to Rs 2089.65. The Company's net profit soared by 32.61% to Rs 60.11 crore, while revenue from operations gained 19.64% to Rs 422.43 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 23.86 lakh crore, easing 6%. It has inched up 2.79% over last one week and surged by 15.59% in last one month while the market capitalization of Corona Remedies Ltd has slipped by 0.78% and 21.60% in the same period respectively. Profit before tax (PBT) of Corona Remedies Ltd stood at Rs 80.36 crore in Q2 FY26, surging by 32.41% year-on-year, and rallying 46.80% quarter-on-quarter. EBITDA came in at Rs 90 crore, expanding by 32.79% YoY and jumping 55.38% sequentially. Total expenses increased by 13.66% to Rs 342.54 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 32.65 crore, advancing by 17.74% YoY, while employee benefits expense was at Rs 122.09 crore, witnessing a strong rise of 14.50% YoY. For the TTM ended FY26, revenue from operations grew 17.28% to Rs 1403.18 crore, while net profit saw a strong growth of 23.88% to Rs 185.12 crore, compared to previous TTM. EBITDA surged by 23376% to Rs 282.79 crore, and PBT surged 21.10% to Rs 240.42 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 229.48 crore in FY26, as against Rs 190.5 crore in FY25. Corona Remedies Ltd rallied 45.40% in last one year, significantly outperforming the benchmark BSE Sensex which has slipped by 4.36% during the same period.